All In Biotech

Drug Trial Radar · NCT07029139

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

A Multicenter, Randomized, Controlled, Open-label Phase II Clinical Study Evaluating the Efficacy and Safety of JMT601 Injection in Participants With Primary Membranous Nephropathy

Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Apr 1, 2027

Study completion Mar 1, 2029

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy. The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

Conditions

  • Primary Membranous Nephropathy

Interventions

  • JMT601 InjectionDrug

    In accordance with the protocol

  • RituximabDrug

    In accordance with the protocol

  • Cyclosporin CapsulesDrug

    In accordance with the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events in Part 1Time frame: Up to 24 weeks
  2. Overall Remission Rate at week 52 in Part 2Time frame: week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.